


REMARKS

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 391442003700.

Respectfully submitted,

Dated: October 15, 2001

By:



Kate H. Murashige

Registration No. 29,959

Morrison & Foerster LLP

3811 Valley Centre Drive

Suite 500


San Diego, California 92130-2332

Telephone: (858) 720-5112

Facsimile: (858) 720-5125

EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE

- (Thrice amended) A compound according to Formula I:



(I)

wherein, W is a nitrogen atom and Y is void or, W is a carbon atom and Y=H;


R¹ to R⁷ may be the same or different and are independently hydrogen or straight, branched or cyclic C₁₋₆ alkyl;

R⁸ is an optionally substituted heterocyclic group or an optionally substituted aromatic group

Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted nitrogen atom and wherein any heteroatom in ring A or B is N;

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a (CH₂)_{n''} group (where n''= 0-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C₁₋₆ alkyl group; a C₀₋₆ alkyl group substituted with an optionally substituted aromatic or heterocyclic group; an optionally substituted C₀₋₆ alkylamino or C₃₋₇ cycloalkylamino group; and an optionally substituted carbonyl group or sulfonyl; and the pharmaceutically acceptable acid addition salts thereof; and

any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

2. (Thrice amended) The compound of claim 1, wherein Ring A is selected from the group consisting of: pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; and triazole; oxazole; and thiazole] and the optionally substituted forms thereof.

3. (Twice amended) The compound of claim 1, wherein Ring B is selected from the group consisting of: benzene[;] and a 5 to 7-membered cycloalkyl ring; [furan; dihydrofuran; tetrahydrofuran; thiophene; dihydrothiophene; tetrahydrothiophene (thiolane); pyran; dihydropyran; tetrahydropyran; thiapyran; dihydrothiapyran; tetrahydrothiapyran (pentamethylene sulfide); oxepine; and thiepin] and the optionally substituted forms thereof.